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Abstract
Background: Long-term survival of HIV-1 infected individuals is usually achieved by continuous administration of 
combination antiretroviral therapy (ART). An exception to this scenario is represented by HIV-1 infected 
nonprogressors (NP) which maintain relatively high circulating CD4+ T cells without clinical symptoms for several years 
in the absence of ART. Several lines of evidence indicate an important role of the T-cell response in the modulation of 
HIV-1 infection during the acute and chronic phase of the disease.
Results: We analyzed the functional and the differentiation phenotype of Nef- and Tat-specific CD8+ T cells in a cohort 
of HIV-1 infected NP in comparison to progressors, ART-treated seropositive individuals and individuals undergoing a 
single cycle of ART interruption. We observed that a distinctive feature of NP is the presence of Nef-specific CD45RA+ 
CD8+ T cells secreting MIP-1beta but not IFN-gamma. This population was present in 7 out of 11 NP. CD45RA+ IFN-
gammaneg MIP-1beta+ CD8+ T cells were not detected in HIV-1 infected individuals under ART or withdrawing from 
ART and experiencing a rebounding viral replication. In addition, we detected Nef-specific CD45RA+ IFN-gammaneg 
MIP-1beta+ CD8+ T cells in only 1 out of 10 HIV-1 infected individuals with untreated progressive disease.
Conclusion: The novel antigen-specific CD45RA+ IFN-gammaneg MIP-1beta+ CD8+ T cell population represents a new 
candidate marker of long-term natural control of HIV-1 disease progression and a relevant functional T-cell subset in 
the evaluation of the immune responses induced by candidate HIV-1 vaccines.
Background
Increasing evidence in humans and in nonhuman primate
models of HIV-1 infection indicates that CD8+ T cells
play a direct role in controlling or limiting HIV-1 replica-
tion. CD8+ T-cell depletion during acute [1] or chronic
[2] SIV infection is associated with a significant increase
in viral load. CD8+ T cells exert a strong selective pres-
sure on SIV [3] and HIV-1 [4], whereas expression of par-
ticular MHC class I alleles correlates with delayed disease
progression in HIV-1 infected individuals [5,6]. However,
long-term control of HIV-1 disease is achieved only in a
minority of infected individuals, and the mechanisms by
which CD8+ T cells contain HIV-1 replication remain
unclear. Indeed, high frequencies of IFN-γ producing
HIV-1-specific CD8+ T cells have been found in nonpro-
gressors (NP) as well as in untreated HIV-1 infected indi-
vidual with progressive disease [7]. The magnitude of the
specific cellular immune response in antiretroviral ther-
apy (ART)-naive individuals generally correlates with
viral load [8-10]. The introduction of polychromatic flow
cytometry technology uncovered a high level of complex-
ity in terms of CD8+ T-cell functional and differentiation
markers, and it is now well accepted that the sole evalua-
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tion of IFN-γ provides limited information on the quality
of antigen-specific CD8+ T-cell responses [11,12].
Indeed, recent studies demonstrated that polyfunctional
HIV-1-specific CD8+ T cells are associated with nonpro-
gressive HIV-1 infection [13]. In addition, measurement
of IFN-γ secretion in combination with the differentia-
tion markers CCR7 and CD45RA revealed an enrichment
of HIV-1-specific, fully differentiated effector cells in NP
[14] and in individuals with early infection and low viral
set point thereafter [15]. In these studies, ART naive indi-
viduals with detectable viremia were chosen as controls
and compared to NP with low or undetectable viremia.
Thus, it was not clear whether these HIV-1-specific T-
cell populations were the cause or the consequence of the
low viremia and of the nonprogressive status. Interest-
ingly, a successive longitudinal study on a cohort of indi-
viduals starting ART and followed for more than two
years showed the emergence of polyfunctional CD8+ T
cells after prolonged suppression of viremia [16], suggest-
ing that polyfunctional CD8+ T cells are lost under the
condition of high antigen exposure and recovered or
maintained when the antigen level is low.
In order to improve our understanding of the relation-
ship between cellular immune response and nonprogres-
sive HIV-1 infection, we analyzed the CD8+ T-cell
response in the peripheral blood compartment of HIV-1
infected individuals with different histories of infection.
Eleven NP were compared to 10 progressors (PR) with
unrestricted control of viral replication. All NP and PR
had not received ART before. In addition, we analyzed 23
ART-treated patients in whom HIV-1 replication is phar-
macologically controlled and the role of the immune sys-
tem is less relevant. Finally, we characterized the immune
response of 6 ART-treated patients who interrupted the
assumption of ART investigating the effect of rebounding
virus replication on the HIV-1-specific CD8+ T cell
responses. W e focused on the role of specific CD8+ T
cells with respect to the non-structural HIV-1 proteins
Nef and Tat. Indeed, these two nonstructural proteins are
known to strongly influence HIV-1 replication, pathoge-
nicity and the host immune response [17,18]. Since previ-
ous studies associated the presence of polyfunctional [13]
and terminally differentiated [14,15,19] CD8+ T cells
with the capacity to control viral replication, we coupled
the simultaneous detection by intracellular staining of 4
functional markers, i.e. IFN-γ, IL-2, CD154 and MIP-1β
with the expression of CD45RA. The use of CD45RA
allowed the discrimination between antigen-specific ter-
minally-differentiated effector CD8+ T cells (CD45RA+),
also termed TEMRA, and the precursor CD45RAneg mem-
ory CD8+ T cells, subdivided into central memory, TCM
and effector memory, TEM. By applying this experimental
setting, we identified a population of HIV-1-specific
CD8+ T cells which is significantly associated with the
N P  c o h o r t ,  c o m p l e t e l y  a b s e n t  i n  t h e  c o h o r t  o f  A R T -
treated patients and not related to the levels of viral repli-
cation.
Results
Nef-specific CD45RA+ IFN-γneg IL-2neg MIP-1β+ CD8+ T cells 
are a specific signature of NP
Nef- and Tat-specific CD8+ T-cell responses were ana-
lyzed by multicolor flow cytometry in a cohort of NP and
compared to responses observed in PR and ART-treated
patients (Table 1). Following stimulation with pools of
overlapping peptides, we simultaneously measured the
expression of CD45RA and the production of IFN-γ, IL-2,
CD154 and MIP-1β. The gating strategy is shown in Fig-
ure 1. We detected Nef-specific CD8+ T-cell responses in
all individuals. However, in 5 ART-treated individuals
and 1 NP, responses were slightly above the threshold
level. NP and PR showed higher frequencies of total Nef-
specific CD8+ T cells when compared to ART-treated
patients (Figure 2A). Correlation analysis showed that
there was no statistically significant correlation between
frequencies of total responses and plasma viral load in the
three cohorts analyzed (data not shown). Nevertheless,
subject NP13 that showed the highest plasma viral load,
had also the highest Nef-specific response.
To assess the quality of the specific responses, we calcu-
lated all possible combinations of IFN-γ, IL-2, MIP-1β
and CD154 expression in the responding CD45RA+ and
CD45RAneg CD8+ T cells. The staining panel was origi-
nally designed as routine immune-assay to evaluate
simultaneously CD4+ and CD8+ T cell responses, and for
this reason includes the measurement of CD154 [20]. As
expected and in agreement with previous reports [21], we
did not find CD8+ T cells expressing CD154, and there-
fore this marker was excluded from the analysis of the
quality of the CD8+ T cell response. Nef-specific
responses were mainly composed of CD45RAneg CD8+
T cells expressing MIP-1β or MIP-1β and IFN-γ (Figure
2B and 2D). The analysis of the quality of the CD8+ T cell
response revealed significant differences between the
three cohorts (Figure 2B). Highly statistically significant
differences (p < 0.01) among the proportion of respond-
ing CD8+ T cells in NP, PR and ART-treated patients
were found in CD45RA+ IFN-γ+ IL-2+ MIP-1β+,
CD45RA+ IFN-γneg IL-2neg MIP-1β+, CD45RAneg
IFN-γ+ IL-2+ MIP-1β+, CD45RAneg IFN-γ+ IL-2neg
MIP-1βneg and CD45RAneg IFN-γneg IL-2+ MIP-1β+
CD8+ T-cell populations. The proportion of polyfunc-
tional (IFN-γ+ IL-2+ MIP-1β+) Nef-specific CD45RA+
CD8+ T cells was significantly higher in NP (median
0.79%; range 0 to 1.90%) than in PR (median 0%; range 0
to 0.03%) or ART-treated individuals (median 0%; range 0
to 1.69%), whereas the proportion of polyfunctionalDembek et al. AIDS Research and Therapy 2010, 7:20
http://www.aidsrestherapy.com/content/7/1/20
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Table 1: Patient characteristics
Patient Years of known seropositivity Years of ART CD4 counts (cells/μl) CD8 counts (cells/μl) HIV-1 RNA Copies/ml of Plasma
NP06 19 - 626 3341 214
NP08 14 - 466 957 720
NP09 17 - 421 864 1100
NP11 19 - 274 747 1800
NP13 13 - 502 967 10756
NP14 20 - 461 464 488
NP15 20 - 532 991 8954
NP16 21 - 1042 1091 50
NP17 23 - 924 1030 1083
NP18 25 - 511 500 900
NP19 9 - 842 914 196
PR03 6 - 466 2322 316212
PR05 0 - 208 237 610000
PR11 6 - 214 808 >500000
PR12 2 - 457 1162 489978
PR25 1 - 474 1180 268919
PR34 10 - 326 2628 113164
PR36 19 - 132 834 >500000
PR77 9 - 226 1265 105488
PR86 1 - 406 2448 99402
PR95 0 - 280 1186 123818
ART12 23 4 413 740 36600
ART14 23 8 470 1926 <40
ART15 22 9 345 478 <40
ART16 23 9 609 888 <40
ART01a 77 9 6 9 7 8 9 < 5 0
ART02a 10 6 609 1033 <50
ART03a 6 6 347 1542 <50
ART04a 44 3 3 4 4 5 5 < 5 0
ART05a 55 6 8 8 6 4 3 < 5 0
ART06a 6 6 455 1378 <50
ART07 23 15 532 840 <50
ART08 23 16 229 833 <50
ART09 13 13 351 281 <50
ART10 22 11 777 850 <40
ART11 24 15 271 1350 3362
ART21 15 4 401 1893 <50
ART23 17 5 954 2403 13965
ART25 16 6 593 1671 <50
ART26 9 4 715 846 <50
ART27 6 5 488 851 <50
ART28 7 6 708 NA <50
ART30 17 13 488 460 <50
ART31 2 2 698 NA <50
a These patients were later enrolled in a single cycle therapy interruption study.Dembek et al. AIDS Research and Therapy 2010, 7:20
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CD45RAneg CD8+ T cells was significantly higher in
ART-treated subjects (median 2.04%; range 0 to 11.9%)
than in PR (median 0.18%; range 0 to 1.69%). On the
other hand, monofunctional Nef-specific CD45RAneg
IFN-γ+ IL-2neg MIP-1βneg CD8+ T cells were detected
in significantly higher proportion in PR (median 13.62%;
range 3.77 to 26.91%) than in NP (median 0.34%; range 0
to 25.78%) and ART-treated individuals (median 4.31%;
range 0 to 28.15%). Surprisingly, the proportion of
responding CD45RA+ IFN-γneg IL-2neg MIP-1β+ CD8+
T cells in NP was significantly higher than in PR and
ART-treated patients with extremely low p values (p =
0.0067 and p = 0.0002, respectively; Figure 2B and 2C).
Indeed, CD45RA+ IFN-γneg IL-2neg MIP-1β+ respond-
ing CD8+ T cells were detected in 7 out of 11 NP (64%)
and 1 out of 10 PR (10%), whereas they were completely
undetectable in the 22 ART-treated patients analyzed
(Nef-specific responses were not analyzed in subject
Figure 1 Gating strategy for the definition of responding and CD45RA+ CD8+ T cells. First, lymphocytes were gated based on FSC versus SSC 
plot (A), followed by exclusion of dead cells by EMA staining (B). As representatively shown, we gated for CD3+ cells on all functional markers to ac-
count for CD3 downregulation in antigen specific responding T-cells and combined these gates with the Boolean operator "OR" to obtain the CD3+ 
cell population (C). As representatively shown, we gated for CD8+ cells on all functional markers to account for CD8 downregulation in antigen spe-
cific responding T-cells and combined these gates with the Boolean operator "OR" to obtain the CD8+ cell population (D). CD4+ T cells were excluded 
from the CD8+ T-cell population. Once the CD8+ T-cell population was defined, cells positive for IFN-γ, MIP-1β, IL-2 and CD45RA were separately iden-
tified by using 4 different plots in which the axis were chosen to provide the best discrimination between positive and negative events (E). The com-
plete gating strategy is shown for patient NP13. Selection of positive cells for the functional markers was done by comparison with a mock-stimulated 
sample.Dembek et al. AIDS Research and Therapy 2010, 7:20
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Figure 2 HIV-1-Nef-specific CD8+ T cell response. HIV-1-Nef-specific CD8+ T cell response in 11 NP (blue), 10 PR (green) and 22 ART-treated indi-
viduals (orange). Nef-specific responses were not analyzed in subject ART07. (A) Frequency of the total Nef-specific CD8+ T cells in NP, PR and ART-
treated individuals. (B) Quality of the Nef-specific response. The graph is divided into the CD45RA+ (left part) and the CD45RAneg (right part) CD8+ T-
cell populations. All the possible combinations of the responses are shown on the x-axis for NP, PR and ART-treated individuals. Tukey boxes and whis-
ker plots are shown. Significant differences are noted above the graph: (*) p < 0.05, (**) p < 0.01 and (***) p < 0.001. Individual data point representation 
of selected HIV-1-Nef-specific CD45RA+ (C) or CD45RAneg (D) CD8+ T-cell populations. Percentages of the total responses are shown for IFN-γneg IL-
2neg MIP-1β+ CD8+ T cells on the left and for IFN-γ+ IL-2neg MIP-1β+ CD8+ T cells on the right. In all graphs, medians are represented by horizontal bars.Dembek et al. AIDS Research and Therapy 2010, 7:20
http://www.aidsrestherapy.com/content/7/1/20
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ART07). Interestingly, Nef-specific CD45RA+ IFN-γneg
IL-2neg MIP-1β+ CD8+ T cells in NP, when detectable,
represented a high proportion of the total response
(range: 10.7 to 49.9%). The same population detected in
one PR (PR05) represented only 6.8% of the total
response. As shown in figures 2C and 2D, the strong
association between CD45RA+ IFN-γneg IL-2neg MIP-
1β+ CD8+ T cells and the NP cohort was a distinctive
feature of this MIP-1β+ cell population and was not
shared with other MIP-1β+ T-cell populations. In fact,
although a significant higher proportion of CD45RA+
IFN-γ+ IL-2neg MIP-1β+ responding CD8+ T cells was
observed in NP in comparison to ART-treated individu-
als (p = 0.0324; Figure 2B and 2C), CD45RA+ IFN-γ+ IL-
2neg MIP-1β+ CD8+ T cells were detectable in PR and
ART-treated individuals and were not uniquely associ-
ated with the NP cohort. Similarly, CD45RAneg Nef-spe-
cific CD8+ T cells either IFN-γneg IL-2neg MIP-1β+ or
IFN-γ+ IL-2neg MIP-1β+ were detected in high frequen-
cies in all the three cohorts (Figure 2B and 2D).
In comparison to Nef-specific responses, Tat-specific
CD8+ T cells were characterized by lower magnitude
and, worthy of note, no significant differences were
observed in the total CD8+ T-cell responses among the
cohorts analyzed (Figure 3A). Significantly higher pro-
portions of Tat-specific CD45RAneg IFN-γ+ IL-2neg MIP-
1βneg and CD45RAneg IFN-γneg IL-2neg MIP-1β+ CD8+ T
cells were observed in NP than in PR and ART -treated
individuals (Figure 3B). Of note, CD45RA+ IFN-γneg IL-
2neg MIP-1β+ responding CD8+ T cells were found in 2
out of 10 NP that showed Tat-specific CD8+ T-cell
responses, while none of the remaining Tat responders in
the other cohorts showed this cell population (Figure 3C).
O v e r a l l ,  w e  o b s e r v e d  t h a t  m o n o f u n c t i o n a l  C D 8 +  T
cells were prevalent in PR whereas polyfunctional CD8+
T cells were prevalent in individuals in whom the viral
load was kept under control either naturally or with the
help of antiretroviral treatment. Of particular interest, we
identified a novel Nef-specific CD45RA+ IFN-γneg IL-2neg
MIP-1β+ CD8+ T-cell population specifically associated
with prolonged spontaneous control of HIV-1 disease
progression in the absence of ART.
Nef- and Tat-specific CD45RA+ IFN-γneg IL-2neg MIP-1β+ 
CD8+ T cells are not driven by viral load
We next explored the potential effect of differences in the
level of viremia on the presence of CD45RA+ IFN-γneg IL-
2neg MIP-1β+ responding CD8+ T cells in NP. Our cohort
of NP was characterized by a prolonged exposure to HIV-
1 antigens since their seropositivity was diagnosed with a
median of 19 years (range: 9-25). In addition, NP showed
detectable plasma viremia, although at low levels (range:
50-10,756 RNA copies/ml). As a consequence, antigen
exposure could have played a direct role in generating
CD45RA+ IFN-γneg IL-2neg MIP-1β+ CD8+ T cells. How-
ever, the analysis of the relationship between plasma vire-
mia and Nef-specific CD45RA+ IFN-γneg IL-2neg MIP-
1β+ CD8+ T cells expressed as percentage of the total
Nef-specific response or as percentage of the total CD8+
T cells revealed no significant correlation (data not
shown). Furthermore, only one PR (10%) showed detect-
able levels of Nef-specific CD45RA+ IFN-γneg  IL-2neg
MIP-1β+ CD8+ T cells, supporting the idea that this
novel CD8 T-cell population is not directly driven by
antigen levels.
To investigate further the role of in vivo HIV-1 replica-
tion in generating CD45RA+ IFN-γneg IL-2neg MIP-1β+
CD8+ T cells, we analyzed Nef- and Tat-specific CD8+ T-
cell responses in a longitudinal set-up. Six ART-treated
patients with highly suppressed viremia (ART01, ART02,
ART03, ART04, ART05 and ART06) underwent a single
cycle of therapy interruption (TI). Viremia became
detectable in all patients between day 5 and 21 after TI.
ART was resumed between day 27 and 185 when viremia
levels reached >100,000 HIV-1 RNA copies/ml. A signifi-
cant expansion of the Nef-specific CD8+ T-cell responses
was observed in all the subjects analyzed (Figure 4A).
However, the quality of the CD8+ T-cell response
remained unchanged in that CD45RA+ IFN-γneg IL-2neg
MIP-1β+ CD8+ T cells remained undetectable even dur-
ing the boost of the total Nef-specific CD8+ T-cell
response that followed the peak of virus replication post
TI (Figure 4B). Of note, we observed a decrease of Nef-
specific CD8+ T cells expressing multiple effector func-
t i o n s  a n d  a n  i n c r e a s e  o f  N e f - s p e c i f i c  C D 8 +  T  c e l l s
expressing solely IFN-γ, but these differences were not
significant, probably due to the low number of subjects
included in the longitudinal analysis. The Tat-specific
CD8+ T-cell response was substantially undetectable
before and after TI (data not shown).
Thus, in our experimental setting CD45RA+ IFN-γneg
IL-2neg MIP-1β+ CD8+ T cells did not appear after induc-
tion of strong in vivo viral replication.
IL-2 is not an essential marker to define the exclusive 
detection of CD45RA+ IFN-γneg IL2neg MIP-1β+ CD8+ T cells 
in NP
Since in our cohorts of HIV-1 infected patients IL-2-pro-
ducing cells were rarely detected, we reanalyzed the data
shown in Figure 2B considering only the combined
expression of CD45RA, IFN-γ and MIP-1β. The propor-
tion of responding CD45RA+ IFN-γneg MIP-1β+ CD8+ T
cells was significantly higher in NP than in PR and ART-
treated patients (p = 0.0069 and p = 0.0012, respectively).
This observation indicates that IL-2 expression repre-
sents neither an essential marker of nonprogressive HIV-
1 infection nor a distinctive feature of CD45RA+ IFN-γneg
MIP-1β+ CD8+ T cells in NP.Dembek et al. AIDS Research and Therapy 2010, 7:20
http://www.aidsrestherapy.com/content/7/1/20
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CD45RA+ IFN-γneg MIP-1β+ CD8+ T cells are truly terminally 
differentiated effector CD8+ T cells
The use of the sole CD45RA marker cannot discriminate
between experienced and naive T-cells, when not associ-
ated with other cellular markers such as CCR7 or CD27.
However, in the present study, we analyzed cells able to
produce cytokines or chemokines following a short (5
hours) antigenic peptide stimulation. Thus, only experi-
enced (memory or effector T-cells) can be detected by
this assay, since the number of circulating naive T-cells
carrying a T-cell receptor specific for a given peptide is
too low to be detected by short term assays. Nevertheless,
we characterized the expression of CCR7 in CD45RA+
IFN-γneg MIP-1β+ CD8+ T cells derived from one HIV-1
infected individual that following treatment interruption
showed a partial control of viral replication (patient V4,
see Materials and Methods). In this patient, Nef-specific
CD45RA+ IFN-γneg MIP-1β+ CD8+ T cells were previ-
ously characterized (unpublished data). As shown in Fig-
ure 5A, Nef-specific CD45RA+ IFN-γneg MIP-1β+ CD8+
T cells were CCR7neg. In the same experiment, we addi-
tionally measured TNF-α expression and observed that
Nef-specific CD45RA+ IFN-γneg MIP-1β+ CD8+ T cells
did not express TNF-α upon antigenic peptide stimula-
tion (Figure 5B).
In conclusion, CD45RA+ IFN-γneg MIP-1β+ CD8+ T
cells did not express the chemokine receptor CCR7 and
are therefore classified as effector CD8+ T-cells (Figure
5A). Furthermore we determined that CD45RA+ IFN-
γneg MIP-1β+ CD8+ T cells did not produce TNF-α in
patient V4 (Figure 5B).
Discussion
A fundamental prerequisite for the development of
immune-based therapies and an effective vaccine against
HIV/AIDS is the identification of solid immune corre-
Figure 3 HIV-1-Tat-specific CD8+ T-cell responses. HIV-1-Tat-specific CD8+ T-cell responses in 10 NP (blue), 10 PR (green) and 23 ART-treated pa-
tients (orange). Tat-specific responses were not analyzed in NP11. (A) Frequency of the total Tat-specific CD8+ T cells. (B) Quality of the Tat-specific 
response. The graph is divided into the CD45RA+ (left part) and the CD45RAneg (right part) CD8+ T-cell populations. All the possible combinations of 
the responses are shown on the x-axis for NP, PR and ART-treated individuals. Tukey boxes and whisker plots are shown. Significant differences are 
noted above the graph: (*) p < 0.05, (**) p < 0.01 and (***) p < 0.001. (C) Individual data point representation of the Tat-specific CD45RA+ IFN-γneg IL-
2neg MIP-1β+ CD8+ T-cells. In all graphs, medians are represented by horizontal bars.Dembek et al. AIDS Research and Therapy 2010, 7:20
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lates of disease progression. In order to identify such cor-
relates, we compared Nef and Tat specific CD8+ T-cell
immune responses in three cohorts of HIV-1 infected
individuals with different degree of HIV-1 control: NP, PR
and ART-treated patients. With this setting, we identified
a novel population of CD8+ T cells associated with non-
progressive HIV-1 infection. CD45RA+ IFN-γneg MIP-
1β+ CD8+ T cells that we henceforth entitle MIRA (MIP-
1β+ CD45RA+) CD8+ T cells potentially represent a
valuable immune correlate of disease progression, since
they were detected in response to Nef stimulation in 7
out of 11 NP, in only 1 out of 10 PR and were completely
absent in 22 ART-treated patients. We further demon-
strated on 6 ART-treated patients undergoing single cycle
TI that the presence of MIRA CD8+ T cells is indepen-
dent of viral load. These observations render this novel
population particularly interesting as a potential surro-
gate clinical marker of immunological reconstitution or
maintenance after immune-based interventions.
According to the expression of CD45RA and CCR7,
antigen-experienced CD8+ T cells are classified as TCM
(CD45RAneg  CCR7+), TEM  (CD45RAneg  CCR7neg) or
TEMRA (CD45RA+ CCR7neg) [22]. Since MIRA CD8+ T
cells express CD45RA and secrete MIP-1β upon specific
antigenic stimulation, they likely belong to the TEMRA
population. The absence of CCR7 expression by MIRA
CD8+ T cells was demonstrated in one representative
sample, further supporting the TEMRA phenotype. Several
studies have suggested a possible role of the fully differen-
tiated HIV-1-specific TEMRA CD8+ T cells in the effective
control of HIV-1 replication: IFN-γ producing TEMRA
CD8+ T cells have been associated with the control of
virus replication in NP [14] and in individuals with early
infection and low viral set point thereafter [15]. Further-
more, antigen-specific TEMRA CD8+ T cells were prefer-
entially detected in acutely infected individuals who
achieved control of viremia either spontaneously or after
structured TI [19]. A pre-terminally differentiation status
or skewed maturation phenotype (mainly composed by
TEM cells) has been reported for HIV-1-specific CD8+ T
cells in therapy-naive viremic patients [23,24]. The
skewed maturation of HIV-1-specific CD8+ T cells in
comparison to other better controlled persistent infec-
tions has been considered as a defective immune
response. Altogether, these studies indicate an important
role of terminally differentiated CD8+ T cells in the con-
trol of HIV-1 replication in vivo. Here we support and
extend the link between HIV-1-specific TEMRA CD8+ T
cells and slow disease progression by identification of a
novel HIV-1-specific population of effector cells specific
for nonprogressive HIV-infection.
Polyfunctional CD8+ T cells have been previously
described in NP [13]. This observation is consistent with
our study, in which the proportion of responding
CD45RA+ IFN-γ+ IL-2+ MIP-1β+ CD8+ T cells was sig-
nificantly higher in NP than in ART-treated individuals (p
= 0.0067; Figure 2B). In addition, we observed higher pro-
portions of polyfunctional CD45RAneg CD8+ T cells in
ART-treated individuals in comparison to PR (Figure 2B)
and higher proportions of monofunctional (IFN-γ+ IL-
2neg MIP-1βneg) CD45RAneg CD8+ T cells in PR in com-
parison to NP and ART-treated individuals (Figure 2B).
These data support the idea that polyfunctional CD8+ T
cells are lost during progressive HIV-1 replication and are
maintained or recovered during nonprogressive infection
Figure 4 Nef-specific CD8+ T-cell responses during TI. (A) Frequency of the total Nef-specific response before and after TI. The median is shown 
for each group. (B) Quality of the Nef-specific CD8+ T-cell responses before (light gray boxes) and after (dark gray boxes) TI. The graph is divided into 
the CD45RA+ (left part) and the CD45RAneg (right part) CD8+ T-cell populations. All possible combinations of responses are shown on the X axis. Tukey 
boxes and whisker plots are shown.Dembek et al. AIDS Research and Therapy 2010, 7:20
http://www.aidsrestherapy.com/content/7/1/20
Page 9 of 13
or treatment with ART. A recent longitudinal study dem-
onstrated that polyfunctional CD8+ T cells re-emerge
following prolonged ART-mediated viral suppression
[16]. Furthermore, Streeck et al. [25] demonstrated that
monofunctional HIV-1-specific CD8+ T cells decrease
upon removal of antigenic stimulation. Together with
these previous studies, our data suggest that persistent
stimulation by antigen can cause functional CD8+ T-cell
impairment and may lead to enrichment of monofunc-
tional IFN-γ producing HIV-1-specific CD8+ T cells.
In chronic viral infections, the main obstacle to the def-
inition of a correlate of disease progression is the ability
to discriminate between phenotypes responsible for the
control of viral replication and phenotypes that are the
consequence of a different infection history [16]. MIRA
CD8+ T cells were undetectable in a group of 4 ART-
treated patients with a previous history as NP (Table 1
and Materials and Methods), suggesting that this cell
population is absent when patients lose the capacity to
control virus replication. The absence of MIRA CD8+ T
cells in 9 out of 10 PR and 3 ART-treated patients with
detectable viremia together with the analysis of a group of
6 ART-treated patients undergoing a single cycle of TI
demonstrated that MIRA CD8+ T cells are not induced
or regulated by the in vivo levels of HIV-1 replication. In
this regard, no correlation was found between the pro-
Figure 5 Characterization of Nef-specific CD45RA+ IFN-γneg MIP-1β+ CD8+ T cells. Total CD8+ T cells of patient V4 are shown according to 
CD45RA/CCR7 (A) and TNF-α/IFN-γ (B) expression. Grey zebra plots show total CD8+ T cells. Percentages of CD45RA+ IFN-γneg MIP-1β+ CD8+ T cells, 
shown as blue dots are indicated in each graph. Mock-stimulated control samples are shown in the left and Nef-stimulated samples in the right panels.Dembek et al. AIDS Research and Therapy 2010, 7:20
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portion of MIRA CD8+ T cells and the levels of viremia
in the 11 NP analyzed, even though the subject with the
highest viremia (NP13) showed also the highest total Nef-
specific response with a large proportion of Nef-specific
MIRA CD8+ T cells (36.5%). These observations suggest
that MIRA CD8+ T cells are not the direct consequence
of ongoing in vivo antigen exposure, but possibly may
represent a correlate of HIV-1 disease progression. How-
ever, it can be suggested that the prolonged exposure to
low levels of plasma viremia in NP is responsible for the
appearance of MIRA CD8+ T cells, and that MIRA CD8+
T cells do not appear following the short term exposure
to high level of viremia during TI. To address this hypoth-
esis it would be helpful to analyze elite controllers, who
are characterized by controlled HIV infection with unde-
tectable viral load. In addition, more detailed longitudinal
studies will be necessary to definitively demonstrate the
role of MIRA CD8+ T cells in HIV-1 infection.
Several reports showed an exceptional HLA class I
associated sequence polymorphism in the nef  and  p24
genes in comparison to other HIV-1 genes [26,27], sug-
gesting a strong selective pressure exerted by CD8+ T
cells targeting Nef and p24. Data from SIV Nef vaccinated
macaques provided evidence that Nef-specific CD8+ T
cells might contribute to the control of SIV infection [28].
Our study was limited to the analysis of the Nef and Tat-
specific CD8+ T-cell responses since these two genes rep-
resent candidate HIV-1 vaccines within the AIDS Vaccine
Integrated Project (AVIP, http://www.avip-eu.org. A
genome-wide analysis of the HIV-1-specific response
using our intracellular cytokine staining analysis will aid
in understanding the role of MIRA CD8+ T cells specific
to p24 and other HIV-1 antigens in the control of viral
replication.
Our study demonstrated that the sole measurement of
the Nef-specific response might be sufficient to define
MIRA CD8+ T cells as a correlate of nonprogression in
HIV-1 disease. In addition, the presence of MIRA CD8+
T cells in 2 Tat-responding NP and the absence of the
same population in the Tat-responding PR and ART-
treated patients suggest that MIRA CD8+ T cells may
represent a correlate of nonprogression independently of
the targeted viral protein. Since, it has been described
that the use of autologous peptides allows the detection
of stronger and broader T-cell responses [29], we cannot
exclude that the use of a set of autologous peptides or the
use of a consensus sequence would have increased the
detection of Tat-specific responses. Further studies
should address which kind of sequence will better suit to
detect MIRA CD8+ T cells specific to different HIV-1
proteins.
HIV-1 infection causes hyperactivation of the immune
system leading to immune exhaustion and disease pro-
gression [30-32]. Since MIRA CD8+ T cells produce nei-
ther IFN-γ nor IL-2, it can be suggested that due to their
limited effector function they do not contribute to hyper-
activation in chronic HIV-1 infection. In contrast, in early
infection, the effector function of CD8+ T cells is essen-
tial in controlling the initial viral replication [33]. Thus,
the limited functionality of MIRA CD8+ T cells may con-
tribute to rapid progression in the early stage of infection.
This could explain why MIRA CD8+ T-cells were
detected in progressor PR05, the only patient within the
PR cohort who presented with the clinical phenotype of a
rapid progressor.
Since the present study was observational, it was not
our objective to clarify whether MIRA CD8+ T cells exert
a direct protective function. However, it has been shown,
that MIP-1β dominates HIV-1-specific CD8+ T-cell
responses [13,34] and that high levels of MIP-1β are asso-
ciated with decreased risk of progression to AIDS [35].
Furthermore, MIP-1β is a potent natural inhibitor of
CCR5-mediated HIV-1 entry [36]. IFN-γ was shown to be
capable to upregulate HIV-1 replication [37,38] and to
induce the expression of HIV in persistently infected cells
in culture [39]. We can therefore speculate that in the
absence of IFN-γ, MIP-1β secreted by MIRA CD8+ T
cells provide HIV-1 inhibitory functions.
Conclusion
In conclusion, our study presents a novel population of
Nef-specific effector CD8+ T cells associated with non-
progressive HIV-1 infection. This population, named
MIRA, expresses CD45RA and produces MIP-1β but not
IFN-γ. This T cell subset was shown to be independent of
in vivo viral replication. MIRA CD8+ T cells may be use-
ful to ameliorate the timing of ART initiation in HIV-1
infected individuals and represent a potential correlate to
determine the efficacy of immune-based interventions.
Materials and methods
Patients
Eleven NP, 10 PR and 23 ART-treated patients were
included in the present study. Of the 11 NP subjects, 10
matched the definition of long-term nonprogressors
(LTNP), i.e. naive to ART with a documented HIV-1
infection of >9 years (median: 19.5 years), CD4+ T-cell
counts ranging between 421 and 1,042 (median: 522 cells/
μl). In comparison to the other NP , study subject NP11
had lower levels of CD4+ T-cell counts (274 cells/μl).
Nevertheless he was included in the NP cohort because
of 19 years of documented history of HIV-1 infection,
with stable CD4+ T-cell counts over a one year follow-up
post-sampling (range: 256-310 cells/μl). The median
plasma viral load in the 11 NP was 900 HIV-1 RNA cop-
ies/ml (range: <50-10756). PR had poor restriction of
viral replication (HIV-1 RNA copies/ml >99000) and
declining CD4+ T-cell counts (median: 303 cells/μl;Dembek et al. AIDS Research and Therapy 2010, 7:20
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range: 132-474). All the PR were ART naive. PR05 was the
only rapid progressor in the PR cohort. Already five
month after putative HIV-1 infection (the timepoint of
blood sampling) CD4+ T-cell counts dropped in this
patient to 208 counts/ml without recovery and persis-
tently high level viremia. The 23 ART-treated patients
were on treatment for 2 or more years. Twenty ART-
treated subjects had undetectable viral load, whereas sub-
jects ART12, ART11 and ART23 had 36600, 3362 and
13965 HIV-1 RNA copies/ml, respectively. The median
CD4+ T-cell count in the 23 ART-treated subjects was
488 cells/μl (range: 229-969). Study subjects ART12,
ART14, ART15 and ART16 were previously classified as
NP but initiated ART more than 4 years before blood
sampling for the present study and therefore are here
included in the ART-treated cohort. Six of the ART-
treated individuals (ART01, ART02, ART03, ART04,
ART05 and ART06) underwent a single cycle of therapy
interruption (TI). From these patients PBMC were
o b t a i n e d  b e f o r e  T I  ( T a b l e  1 )  a n d  a t  t h e  p e a k  o f  t h e
immune response after TI. Viremia was monitored
weekly and treatment restarted at the first viral load
determination >100,000 HIV-1 RNA copies/ml. Patients
remained off treatment for a median of 31 days (range:
26-182 days). HIV-1 infected patient V4 was due to his
clinical characteristics not member of any of the above
described cohorts. At the timepoint of blood sampling (3
years after TI) viral replication was controlled to 48600
HIV-1 RNA copies/ml. CD4 T-cell counts before and
after blood sampling were 758 and 871 cells/μl, respec-
tively.
The study was approved by the local Institutional
Review Boards (Comitato Etico - Ospedale San Raffaele;
Ethic Commitee of the Azienda Ospedaliera della Provin-
cia di Lodi; Ethikkommission der Medizinischen Fakultät
der Ludwig-Maximilians-Universität München; Ethik-
kommission der Ärztekammer Hamburg). Written
informed consent was obtained for all study participants.
Antibodies
CD3-AmCyan, CD4-PerCP, CD45RA-PE-Cy7, CD154-
FITC, IFNγ-Al700, IL2-APC and MIP-1β-PE were
obtained from Becton Dickinson. CD8-PacB was
obtained from DAKO. CCR7-FITC and TNFα-PacB were
obtained from R&D and NatuTec, respectively.
Antigens
Nef- and Tat-specific cellular responses were identified
by using two sets of overlapping peptides covering the
HIV-1 encoded Tat (BH10 strain) and Nef (BRU strain)
antigens. Nef peptides were divided into 2 pools: Nef N-
term (amino acids 1 to 101) and Nef C-term (amino acids
97 to 206). All pools were used at the final concentration
of 2 μg/ml of each peptide. The Tat- and Nef-specific sets
of overlapping peptides have been designed using a strat-
egy termed Variable Overlapping Peptide Scanning
Design (VOPSD) [40] that has been validated within the
EU-sponsored AVIP consortium by a ring trial involving
5 different European and South African laboratories.
Briefly, all peptides were biased at the C-terminus
avoiding 7 amino-acid residues never found among opti-
mal CTL epitopes and MHC class I binding motifs (Asn,
Asp, Gln, Glu, Gly, His, Ser). Optimal epitopes were
placed in the N- or C-terminus of the peptides. Finally,
conserved and variable regions were segregated in differ-
ent peptides. In order to fit all the above mentioned
design features the derived peptides were conceived to be
variable in length (10 to 19 amino-acids) and degree of
overlap (5 to 14 amino-acids, with a gap ≤8 amino-acids).
Moreover, the degree of overlap and the overall peptide
length were empirically tuned according to the frequency
of known T-cell epitopes (higher overlap and shorter pep-
tide length in epitope-rich regions and, conversely, wider
not-overlapping fragment and maximal peptide length in
epitope-poor regions). Peptides were obtained through
the Centre for AIDS Reagents, National Institute for Bio-
logical Standards and Control, Hertfordshire, UK.
Intracellular cytokine staining
Cryopreserved samples were used throughout the study.
The 9-color intracellular cytokine staining used in the
present study has been previously described [34]. Briefly,
all the incubations were carried out in round-bottom 96-
well plates to allow high-throughput processing of the
probes. 106 PBMC per well were incubated with 1.3 μg/ml
of anti-CD28 mAb and with 1.3 μg/ml of anti-CD49d
mAb (Becton Dickinson) together with defined peptide
pools. For each individual donor, a sample without pep-
tides was included to calculate the background staining.
Following 60 min incubation, 10 μg/ml of Brefeldin A
(Sigma) were added to the cell suspension and the incu-
bation was carried out for additional 4 h. Stimulated cells
were then resuspended in Stain Buffer (0.2% BSA, 0.09%
N a  A z i d e  i n  D u l b e c c o ' s  P B S ;  B e c t o n  D i c k i n s o n )  a n d
incubated with the photoreactive fluorescent label ethid-
ium monoazide (EMA; Molecular Probes) to assess their
viability. After washing, cells were fixed and permeabi-
lized using the BD Cytofix/Cytoperm™ Kit (Becton Dick-
inson). Then fluorochrome-conjugated Abs were added
to the cell suspension. Incubation was carried out on ice
for 30 min and after washing, cells were acquired using an
LSRII flow cytometer (Becton Dickinson) equipped with
a high throughput system. Sample analysis was per-
formed using FlowJo version 8 (Tree Star). Lymphocytes
were gated on a forward scatter area versus side scatter
area pseudo-color dot plot and dead cells were removed
according to EMA staining. Events were gated on CD3+
events versus IFN-γ, IL-2, MIP-1β and CD154 to accountDembek et al. AIDS Research and Therapy 2010, 7:20
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for down-regulation. CD3+ events were then combined
together using the Boolean operator "OR". The same pro-
c e d u r e  w a s  u s e d  t o  s u b s e q u e n t l y  g a t e  C D 8 +  e v e n t s .
CD 4 +  ev e n t s  w e r e  e x c l u d e d  be f o r e  c r e a t i n g  a  g a t e  f o r
each function or phenotype as shown in Figure 1. In con-
sistency with others [41,13,42] positive events were deter-
mined by gating on combinations of markers that
provided optimal separation between positive and nega-
tive populations. Each gate selected all cells positive for
the marker shown on the x-axis, while the marker chosen
on the y-axis was selected to provide a better separation
between positive and negative events. By calculating
every possible combination of the 5 populations gated in
Figure 1, Boolean gating analysis identified 32 response
patterns. Response patterns with at least 1 positive func-
tional marker were taken into consideration for analysis,
thus resulting in a total of 30 immune response patterns.
Statistical analysis
Since background levels varied between subpopulations,
i.e. MIP-1β staining showed a higher background than
IFN-γ, and the combination of 3 or more functions had
extremely low background, we calculated a threshold
level for each subpopulation. Following background sub-
traction, the threshold level was calculated using the 90th
percentile of the negative values. Then, all the resulting
negative values were set to zero and all values >0 were
considered as positive responses. The frequency of the
total CD8+ T cell response was calculated by summing
each unique CD8+ T-cell population expressing at least
one functional marker. Percentages of total responses
were calculated by dividing the frequency of each sub-
population by the frequency of the total CD8+ T cell
response. In order to analyze the quality of the response
without considering the CD154 marker, the CD154+ and
CD154neg CD8+ T-cell populations were combined using
SPICE software. SPICE version 4.1.5 (Mario Roederer,
Vaccine Research Center, National Institute of Allergy
and Infectious Diseases, National Institutes of Health)
and Prism version 5.01 (GraphPad Software) were used
for graphical representation of the data and statistical
analysis. To compare paired groups, the Wilcoxon
signed-rank test was performed. To account for multiple
comparisons, a closed testing procedure was applied in
testing differences of all groups by the Kruskal-Wallis test
followed by pair-wise comparisons with the Wilcoxon
rank sum test. The SAS Version 9.1 was used to get exact
P values for the statistical analysis.
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